Skip to main content

Table 2 Clinicopathological characteristics between two non-pCR group (SUVmax reduction rate (<60% or ≥60%)

From: SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma

Characteristic, n (%) SUVmax reduction rate P
< 60% ≥ 60%
n=23 n=44
The interval days between NACRT finished and FDG-PET taken 20 (10–46) 20 (6–32) 0.5705
Median age (range) 65 (47–75) 63.5 (41–75) 0.5083
Gender    0.7546
Female 3 (13.0) 7 (15.9)  
Male 20 (87.0) 37 (84.1)  
Tumor location    0.8080
Upper 5 (21.7) 10 (22.7)  
Middle 10 (43.5) 22 (50.0)  
Lower 8 (34.8) 12 (27.3)  
Tumor differentiation    0.7346
Not poorly 21 (91.3) 39 (88.6)  
Poorly 2 (8.7) 5 (11.4)  
Depth of invasion (cT)    0.7813
T1-2 2 (8.7) 3 (6.8)  
T3-4 21 (91.3) 41 (93.2)  
Lymph node metastasis (cN)    0.8980
N1 15 (65.2) 28 (63.6)  
N2-3 8 (34.8) 16 (36.4)  
Distant metastasis (cM)    0.0804
M0 19 (82.6) 42 (95.5)  
M1 ( Lymph node) 4 (17.4) 2 (4.6)  
Clinical stage(cStage)    0.0615
I 2 (8.7) 0 (0)  
II 0 (0) 3 (6.8)  
III 17 (7.39) 38 (86.4)  
IVA 0 (0) 1 (2.3)  
IVB 4 (17.4) 2 (4.6)  
Recurrence    0.0445a
Presence 15 (65.2) 17 (38.6)  
Absence 8 (34.8) 27 (61.4)  
Prognosis    0.1752
Alive 10 (43.5) 31 (70.5)  
Dead with ESCC 11 (47.8) 10 (22.7)  
Dead with other diseases 2 (8.7) 3 (6.8)  
  1. *Statistically significant